Ajanta Pharma Limited saw an additional 26,21,067 equity shares pledged by its promoter group entities to secure debt instruments issued by affiliated companies. The disclosure was filed by CTL Trusteeship Limited, acting as the common security trustee.

The pledge supports secured, unlisted, redeemable, and non-convertible debentures issued by Lenexis Foodworks Private Limited and Inspira Realty 2 Private Limited. The total value of these debentures aggregates to ₹3,873 crore, comprising ₹3,373 crore from Lenexis Foodworks and ₹500 crore from Inspira Realty 2.

Pledge Details and Timeline

The additional pledge comprises two tranches executed in late 2026. Specifically, 21,61,067 shares were pledged on July 24, 2026, and 4,60,000 shares were pledged on September 28, 2026. These actions increased the total number of pledged shares held by the security trustee.

The entities involved in creating this encumbrance include Aayush Agrawal Trust, Aayush Agrawal, and Gabs Investments Private Limited. Under the transaction documents, these entities have undertaken covenants that constitute an encumbrance on their shareholding in Ajanta Pharma as defined under SEBI regulations.

Impact on Shareholding Structure

Following this additional pledge, the total number of pledged shares rose to 92,53,718. This represents 7.41% of the company's total voting capital, up from 5.31% prior to this transaction. The total diluted share capital of Ajanta Pharma stands at ₹25,01,71,848, corresponding to 12,50,85,924 equity shares with a face value of ₹2 each.

What the Numbers Show

While the specific pledge of shares increased by 26,21,067 units, the total number of encumbered shares (including those under covenants) decreased slightly from 1,69,12,924 to 1,63,32,924. This divergence suggests that some existing encumbrances or covenants may have been released or restructured concurrently with the new pledge creation, resulting in a net marginal decrease in total encumbered holdings despite the addition of new pledged collateral.

The disclosure was made pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, highlighting the ongoing leverage within the promoter group's financial structure linked to non-listed entities.

Ajanta Pharma Limited has submitted its voluntary Sustainability Report for FY26, prepared with reference to GRI Standards. The disclosure highlights a 47% reduction in Scope 1 emissions and the achievement of zero workplace fatalities across its operations during the fiscal year.

The report, filed under Regulation 30 of SEBI (LODR) Regulations, 2015, complements the mandatory Business Responsibility and Sustainability Report (BRSR). It details the company's environmental, social, and governance initiatives, including a significant expansion in renewable energy capacity to 16.6 MW, which now meets 34% of total energy needs.

Environmental Performance and Decarbonisation

The company achieved a substantial decrease in direct greenhouse gas emissions, reducing Scope 1 emissions from 6,392 tCO2e in the prior year to 3,364 tCO2e in FY26. This reduction was driven by the commissioning of additional solar power installations and the replacement of fossil fuels with biomass-fired boiler systems at key facilities.

Combined Scope 1 and Scope 2 emissions remained flat at approximately 49,940 tCO2e despite revenue growth, indicating improved operational efficiency. Water stewardship efforts included Zero Liquid Discharge practices across manufacturing facilities and rural conservation projects creating 1.5 lakh KL of annual potential.

Social Impact and Workplace Safety

Ajanta Pharma reported zero fatalities, high-consequence injuries, or lost-time injuries across 10,404 employees and 2,802 workers. Six major sites are certified for ISO 14001 and ISO 45001 standards. The company maintained its Great Place To Work certification for the fourth consecutive year and was named a Most Preferred Workplace for Women.

Community engagement saw a CSR spend of ₹23.73 crore, exceeding the statutory obligation by 18.1%. This funding reached 3.63 lakh people through health, education, and sports initiatives. Additionally, 28% of input material was sourced from MSMEs and small producers, up from 15% in the previous year.

Governance and Operational Highlights

Governance structures were strengthened with formal AI-risk identification across R&D, manufacturing, and supply chain functions. The Board comprises 25% women directors, and 100% of senior management is covered under the Code of Conduct. No whistle-blower complaints, bribery incidents, or data breaches were recorded during the year.

What the Numbers Show

The juxtaposition of flat combined Scope 1 and 2 emissions against reported revenue growth suggests that Ajanta Pharma’s decarbonisation efforts are effectively offsetting the carbon intensity typically associated with increased production volumes. The shift from incineration to co-processing for hazardous waste, where landfill disposal dropped to 0.7 MT, further indicates a strategic pivot toward circular economy principles rather than mere compliance.